Photo of Dina Titus
D United States House · District 1 · Nevada On the 2026 ballot

Rep. Dina Titus

Compare
Total votes
2,837
all sessions
Attendance
96%
119 missed
Lower than 92% of chamber peers
With party
97%
of cast votes
Near the chamber average
Bipartisan score
1%
crosses aisle rarely
Near the chamber average
Sponsored
2,674
bills & resolutions
Higher than 97% of chamber peers
Committees
8
assignments
2,674 bills and resolutions

Sponsored bills

Total
2,674
Primary
132
Co-sponsor
2,542
This page
2,674
matching current filters
Co-sponsor HR 1262
Passed · United States House · Co-sponsor
Mikaela Naylon Give Kids a Chance Act

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Passed Dec 2, 2025 1 co-sponsor
Co-sponsor HR 5697
In committee · United States House · Co-sponsor
Passenger Rail Liability Adjustment Act of 2025

Maddy summaryHR 5697, the Passenger Rail Liability Adjustment Act of 2025, sets the effective date for adjustments to the liability cap for passenger rail operators. Specifically, any adjustment to the liability cap under federal law that occurs during 2026 must take effect 90 days after a required notice is issued. This procedural bill does not change the liability cap amount itself but establishes a clear timeline for when such adjustments become effective. It directly affects passenger rail operators subject to the liability cap under 49 U.S.C. § 28103.

In committee Dec 1, 2025 1 co-sponsor
Co-sponsor HRES 909
In committee · United States House · Co-sponsor
Recognizing that immigrant justice and reproductive justice are inseparable and must be pursued together.

Maddy summaryHRES 909 is a House resolution affirming that immigrant justice and reproductive justice are interconnected and must be addressed together. It calls on the Department of Homeland Security to reinstate protections for pregnant individuals in detention, eliminate the 5-year bar restricting immigrants’ access to federal health programs like Medicaid, and implement transparent oversight of reproductive health care in detention facilities. The resolution also urges Congress to remove barriers to health care access for immigrants and requires federal agencies to report on policies affecting reproductive health care for detained individuals. This resolution directly affects policies toward immigrants in detention, particularly regarding access to abortion, prenatal care, and mental health services, but does not create new laws.

In committee Nov 21, 2025 1 co-sponsor
Co-sponsor HR 6268
In committee · United States House · Co-sponsor
LEAD Act of 2025

Maddy summaryHR 6268, the LEAD Act of 2025, requires the use of non-lead ammunition on all lands and waters managed by the U.S. Fish and Wildlife Service (USFWS), effective one year after enactment. It directly affects hunters and recreational shooters using USFWS lands, with exceptions for law enforcement, military personnel, and government officials performing official duties. The bill mandates the USFWS to establish a list of certified non-lead ammunition (defined as containing ≤1% lead by weight) and imposes civil penalties of up to $500 for first violations and $1,000-$5,000 for repeat offenses. This policy aims to protect wildlife, human health, and food safety by reducing lead exposure from spent ammunition, which the bill cites as a documented risk to ecosystems and consumers.

In committee Nov 21, 2025 1 co-sponsor
Co-sponsor HR 6282
In committee · United States House · Co-sponsor
Providing Distance Education for Foreign Institutions Act

Maddy summaryThis bill modifies the Higher Education Act to allow foreign institutions of higher education to offer distance learning courses that qualify for federal student aid. It sets three key requirements: distance education must not exceed 12.5% of a program, the institution must be evaluated by an outside accreditor, and students must physically attend instruction in the foreign country. The changes apply to foreign institutions seeking to provide hybrid programs where students receive aid under the Higher Education Act. The rules take effect after enactment, with a 3-month implementation period for the first qualifying semester.

In committee Nov 21, 2025 1 co-sponsor
Co-sponsor HR 6286
In committee · United States House · Co-sponsor
Indo-Pacific Partner and Ally Tariff Repeal Act

Maddy summaryHR 6286, the Indo-Pacific Partner and Ally Tariff Repeal Act, repeals tariffs imposed on 39 specific Indo-Pacific countries and territories through two executive orders. The bill directly affects these nations, including Australia, Japan, India, South Korea, and others, by eliminating tariffs that were applied under Executive Orders 14257 and 14326. Its key provision requires the immediate termination of these tariffs upon the bill's enactment. The legislation targets only the listed countries and does not alter tariffs on other nations.

In committee Nov 21, 2025 1 co-sponsor
Co-sponsor HR 6215
In committee · United States House · Co-sponsor
Small Business RELIEF Act

Maddy summaryHR 6215, the Small Business RELIEF Act, exempts small businesses from import duties imposed under Executive Order 14257 (90 Fed. Reg. 15041) for goods they import or use. It requires the President to refund duties paid by small businesses within 90 days of the bill's enactment. The bill defines "small business concern" using the standard Small Business Act criteria (15 U.S.C. 632). This directly affects small businesses importing goods, providing immediate cost relief by removing a specific tariff and refunding past payments.

In committee Nov 20, 2025 1 co-sponsor
Co-sponsor HR 6204
In committee · United States House · Co-sponsor
Large-Scale Water Recycling Reauthorization Act

Maddy summaryHR 6204 extends funding authorization for large-scale water recycling projects by changing the Infrastructure Investment and Jobs Act's Section 40905(k) from a 5-year to a 10-year period. This procedural bill directly affects existing water recycling projects currently funded under the Infrastructure Investment and Jobs Act (Public Law 117-58). The key provision is simply the extension of the authorization period, providing longer-term stability for these projects without creating new programs or altering eligibility.

In committee Nov 20, 2025 1 co-sponsor
Co-sponsor HR 6166
In committee · United States House · Co-sponsor
Lowering Drug Costs for American Families Act

Maddy summaryThis bill expands Medicare's drug price negotiation program to cover 50 drugs (up from 20) and requires health insurers to apply negotiated prices to cost-sharing for beneficiaries. It establishes annual out-of-pocket cost-sharing limits for prescription drugs under group health plans and insurance coverage, with specific limits of $2,000 for self-only coverage in 2027 that will increase annually. The bill also sets specific cost-sharing limits for insulin products, requiring coverage with no deductible and cost-sharing of no more than $35 per 30-day supply or 25% of the negotiated price. These provisions affect Medicare beneficiaries, people with group health plans, and health insurers across the country. The bill applies to plan years beginning on or after January 1, 2027.

In committee Nov 20, 2025 1 co-sponsor
Co-sponsor HR 6181
In committee · United States House · Co-sponsor
John Lewis Every Child Deserves a Family Act

Maddy summaryHR 6181, the John Lewis Every Child Deserves a Family Act, prohibits child welfare agencies receiving federal funds from discriminating against children, youth, or prospective foster/adoptive parents based on religion, sex (including sexual orientation and gender identity), or marital status. It directly affects LGBTQ youth in foster care - overrepresented at 30% of the system - who face higher risks of trauma, group home placements, and suicide attempts compared to non-LGBTQ peers. Key provisions require agencies to collect data on sexual orientation and gender identity, establish a National Resource Center for LGBTQ youth support, provide cultural competency training, and eliminate discriminatory practices. The law aims to improve safety, permanency, and placement stability by expanding access to family-based care and ensuring equitable services for all children in the system.

In committee Nov 20, 2025 1 co-sponsor
Showing 281 to 290 of 2,674 bills
Previous 1 … 28 29 30 … 268 Next